Semaglutide Dosing & Protocols — Research Reference

Semaglutide is a GLP-1 receptor agonist with the largest published trial dataset in the incretin class (SUSTAIN, STEP, PIONEER programs). This guide compiles standard titration and dosing references from that literature.

Reconstitution for Research

Standard reconstitution: 5–10 mg lyophilized peptide with 1–2 mL bacteriostatic water. Refrigerated stability extends 30+ days post-reconstitution per typical COA.

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Initiation | 0.25 mg/week × 4 weeks | Standard entry titration step | | Intermediate | 0.5–1.0 mg/week | Glycemic-endpoint maintenance per SUSTAIN data | | High tier | 1.7–2.4 mg/week | Body-composition endpoints per STEP trial data |

Scheduling

Weekly subcutaneous administration. Steady-state at ~4–5 weeks given the ~165h half-life. Single fixed day-of-week with rotating injection sites is the published norm.

Cycling in the Published Literature

Continuous administration with quarterly titration steps dominates the published literature. Discontinuation studies show metabolic markers begin regression within 12 weeks.

Common Research Endpoint Markers

HbA1c, fasting glucose, body weight, waist circumference, lipid panel, hepatic markers. GI tolerability tracked across all studies.

Common Research Pairings

Most-cited pairing is semaglutide + [cagrilintide](/research/hubs/cagrilintide) (CagriSema) for amylin-pathway complementarity. Direct pairing with tirzepatide is not standard (mechanism overlap).

Storage & Stability

Lyophilized at 2–8 °C protected from light. Reconstituted refrigerated. Stable across the standard cold-chain.

Frequently Asked Questions

Can semaglutide be administered orally?

An oral SNAC-coformulated semaglutide research formulation exists (PIONEER program). Bioavailability is much lower than subcutaneous, requiring higher daily doses.

Why is the GI signal strongest during titration?

Rapid up-titration produces gastric-emptying changes that trigger nausea before adaptation. The 4-week step protocol allows gastric tolerance to develop.

Research-Use Disclosure

All content is provided strictly for laboratory research purposes. Compounds discussed are research chemicals and are not for human or veterinary consumption. Dosing ranges referenced below are summaries of published preclinical and clinical research literature compiled for laboratory reference only — they are not medical recommendations.